A detailed history of Hrt Financial LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 10,088 shares of MDGL stock, worth $3.14 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
10,088
Holding current value
$3.14 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$212.22 - $292.96 $2.14 Million - $2.96 Million
10,088 New
10,088 $2.14 Million
Q4 2023

Feb 09, 2024

BUY
$120.4 - $237.13 $447,406 - $881,175
3,716 New
3,716 $859,000
Q1 2023

May 12, 2023

BUY
$231.06 - $307.08 $543,222 - $721,945
2,351 Added 21.53%
13,270 $3.21 Million
Q4 2022

Feb 10, 2023

BUY
$58.39 - $296.54 $637,560 - $3.24 Million
10,919 New
10,919 $3.17 Million
Q1 2022

May 16, 2022

SELL
$55.89 - $101.89 $535,929 - $977,023
-9,589 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$72.34 - $95.09 $693,668 - $911,818
9,589 New
9,589 $812,000
Q3 2021

Nov 15, 2021

SELL
$78.35 - $105.02 $842,967 - $1.13 Million
-10,759 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$97.2 - $137.59 $1.05 Million - $1.48 Million
10,759 New
10,759 $1.05 Million
Q4 2020

Feb 16, 2021

SELL
$110.06 - $133.7 $772,511 - $938,440
-7,019 Closed
0 $0
Q3 2020

Nov 13, 2020

BUY
$99.78 - $124.21 $700,355 - $871,829
7,019 New
7,019 $833,000
Q4 2019

Feb 14, 2020

SELL
$84.28 - $118.5 $355,408 - $499,714
-4,217 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$84.4 - $106.53 $355,914 - $449,237
4,217 New
4,217 $363,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.32B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.